429 related articles for article (PubMed ID: 19502270)
1. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
3. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
4. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.
Lampropoulos CE; Sangle S; Harrison P; Hughes GR; D'Cruz DP
Rheumatology (Oxford); 2004 Nov; 43(11):1383-5. PubMed ID: 15266063
[TBL] [Abstract][Full Text] [Related]
5. [Classification of dermatologic manifestations in lupus erythematosus].
Francès C; Barete S; Ayoub N; Piette JC
Ann Med Interne (Paris); 2003 Feb; 154(1):33-44. PubMed ID: 12746657
[TBL] [Abstract][Full Text] [Related]
6. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Aymard G; Leroux G; Marra D; Lechat P; Piette JC
Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
[TBL] [Abstract][Full Text] [Related]
7. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Feldmann R; Salomon D; Saurat JH
Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
[TBL] [Abstract][Full Text] [Related]
8. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
Costedoat-Chalumeau N; Amoura Z; Huong DL; Lechat P; Piette JC
Autoimmun Rev; 2005 Feb; 4(2):111-5. PubMed ID: 15722258
[TBL] [Abstract][Full Text] [Related]
9. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Costedoat-Chalumeau N; Amoura Z; Duhaut P; Huong DL; Sebbough D; Wechsler B; Vauthier D; Denjoy I; Lupoglazoff JM; Piette JC
Arthritis Rheum; 2003 Nov; 48(11):3207-11. PubMed ID: 14613284
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine in lupus pregnancy.
Clowse ME; Magder L; Witter F; Petri M
Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
[TBL] [Abstract][Full Text] [Related]
11. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
Ang GC; Werth VP
Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
[TBL] [Abstract][Full Text] [Related]
12. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
Jewell ML; McCauliffe DP
J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
[TBL] [Abstract][Full Text] [Related]
13. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.
Costedoat-Chalumeau N; Hulot JS; Amoura Z; Leroux G; Lechat P; Funck-Brentano C; Piette JC
Rheumatology (Oxford); 2007 May; 46(5):808-10. PubMed ID: 17202178
[TBL] [Abstract][Full Text] [Related]
14. Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
Creel N; Werth V
J Drugs Dermatol; 2005; 4(2):225-7. PubMed ID: 15776783
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T
Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus 1% cream for cutaneous lupus erythematosus.
Kreuter A; Gambichler T; Breuckmann F; Pawlak FM; Stücker M; Bader A; Altmeyer P; Freitag M
J Am Acad Dermatol; 2004 Sep; 51(3):407-10. PubMed ID: 15337984
[TBL] [Abstract][Full Text] [Related]
18. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Hammoud HA; Aymard G; Cacoub P; Francès C; Wechsler B; Huong du LT; Ghillani P; Musset L; Lechat P; Piette JC
Arthritis Rheum; 2006 Oct; 54(10):3284-90. PubMed ID: 17009263
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial agents and lupus.
Wallace DJ
Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.
Williams HJ; Egger MJ; Singer JZ; Willkens RF; Kalunian KC; Clegg DO; Skosey JL; Brooks RH; Alarcón GS; Steen VD
J Rheumatol; 1994 Aug; 21(8):1457-62. PubMed ID: 7983646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
